DACOTA Phase III Study of Decitabine vs Hydroxyurea for Advanced Proliferative CMML

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this phase III study in patients with newly diagnosed advanced myeloproliferative CMML comparing decitabine vs hydroxyurea no differences in EFS, OS, or transformation to AML were reported.
Format: Microsoft PowerPoint (.ppt)
File Size: 306 KB
Released: December 14, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seagen
Takeda Oncology

Related Content

Preliminary results for ropeginterferon alfa-2b in prefibrotic primary low/intermediate-1 risk myelofibrosis, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 17, 2022

Phase I study evaluating selinexor + ruxolitinib in previously untreated myelofibrosis, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 17, 2022

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on management strategies for MF

Srdan Verstovsek, MD, PhD
Program Director
Brady L. Stein, MD, MHS person default Abdulraheem Yacoub, MD
Released: December 16, 2022

Results from phase II REFINE cohort 3 evaluating navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis, from ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings